MARKET NEWS

BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections, Including COVID-19
Menlo Therapeutics & Foamix Pharmaceuticals Complete Merger
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 Study
10 Drugs in Pre-Registration Phase Have Potential to Reach Blockbuster Status by 2025
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment & Prevention of Coronavirus Disease
Beroni Group Advances Research & Development of Medical Solution for Coronavirus (COVID-19)

  FEATURED EDITORIAL

  COMPANY PROFILE

Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering for our customers. Employing around 6,000 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. For over 20 years we have been there for our clients throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again. Click here for more.

Looking for an experienced and committed steriles CDMO? Look no further than Pii. Pii has a strong pedigree of scientific know-how and regulatory experience across a range of dosage forms, including capacity for aseptic fill-finish. Our commitment to this market and our capabilities have grown further with investment in a new, fully-robotic aseptic filling line. With expanded capacity for small to medium-batch production of commercial and clinical materials, we are eager to discuss your needs, so we can help advance your sterile product. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Evonik Achieves Major Biotech Breakthrough With a New Animal-Free & Fermentation-Based Collagen Platform

Evonik Achieves Major Biotech Breakthrough With a New Animal-Free & Fermentation-Based Collagen Platform

Evonik recently announced the development of an advanced collagen platform that is made via fermentation-based processes and devoid of animal- or human-derived materials…..

Tyligand Bioscience & Context Therapeutics Sign Strategic Development Agreement for Onapristone ER

Tyligand Bioscience & Context Therapeutics Sign Strategic Development Agreement for Onapristone ER

Tyligand Bioscience and Context Therapeutics LLC recently announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of….

Nurix Therapeutics Closes 0-Million Financing to Advance Targeted Protein Modulation Drug Pipeline

Nurix Therapeutics Closes $120-Million Financing to Advance Targeted Protein Modulation Drug Pipeline

With the funds raised in this financing, Nurix is well positioned to bring its targeted protein modulation therapeutics into the clinic…..

Zydus & XOMA Announce Exclusive Licensing Agreement

Zydus & XOMA Announce Exclusive Licensing Agreement

Zydus Cadila and XOMA Corporation recently announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that….

DEINOVE Passes Second Milestone of the AGIR Program

DEINOVE Passes Second Milestone of the AGIR Program

DEINOVE recently announced it has successfully completed the second key milestone of the AGIR program – Antibiotics against Resistant Infectious Germs – which is supported by……

Ajinomoto Bio-Pharma Services Announces Formation of External Advisory Board

Ajinomoto Bio-Pharma Services Announces Formation of External Advisory Board

Ajinomoto Bio-Pharma Services recently announced the formation of its External Advisory Board (EAB) to provide insight into industry trends and…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 25 – Parenteral Contract Manufacturing
April 1 – Polymers & Biomaterials